5.4 Managing Lost to Follow-Up, Subject Withdrawal & Early Termination Procedures
Key Takeaways
- A participant has the absolute ethical and regulatory right under ICH E6(R3) Annex 1 2.8 and 21 CFR 50.25 to withdraw from a clinical trial at any time, for any reason, without penalty or loss of entitled benefits.
- Classifying a subject as Lost to Follow-Up (LTFU) requires exhaustive, documented due diligence, including repeated phone attempts at varied hours, contacting secondary emergency contacts, and sending a certified letter with return receipt requested.
- Discontinuation of investigational product intervention must be clearly distinguished from complete withdrawal of consent; participants who stop study medication should be encouraged to continue safety and survival follow-up.
- Per FDA Guidance (2008) and ICH GCP, data collected on a participant prior to consent withdrawal cannot be removed from the trial database and remains part of the permanent study record.
- Early Termination (ET) visits ensure participant safety by conducting final physical exams, laboratory panels, adverse event evaluations, and investigational product reconciliation.
Managing Lost to Follow-Up, Subject Withdrawal & Early Termination Procedures
Core Ethical Standard: Under ICH GCP E6(R3) Annex 1 section 2.8 and 21 CFR 50.25(a)(8), human participants participate in clinical trials purely on a voluntary basis. A participant may withdraw from the trial at any time, for any reason or no reason, without penalty, loss of benefits to which they are otherwise entitled, or compromise to their ongoing standard medical care. When a participant becomes unresponsive or chooses to withdraw, clinical research professionals must execute structured, GCP-compliant procedures to ensure subject safety, fulfill regulatory due diligence, and preserve clinical data integrity.
1. Lost to Follow-Up (LTFU): Definition & Methodological Impact
A participant is considered Lost to Follow-Up (LTFU) when they cease attending scheduled study visits and completely stop communicating with the investigative site, and the site is unable to establish contact despite exhaustive tracing efforts.
┌──────────────────────────────────────────────────────────────────────────┐
│ METHODOLOGICAL HAZARDS OF LTFU │
├──────────────────────────────────────────────────────────────────────────┤
│ 1. Attrition Bias: If dropouts are related to treatment toxicity or │
│ lack of efficacy, remaining subjects present a skewed safety profile.│
│ 2. Loss of Statistical Power: Missing endpoint data reduces the study's │
│ mathematical ability to detect true therapeutic differences. │
│ 3. Obscured Fatalities & Severe Toxicities: An uncontactable subject may│
│ have suffered a fatal SAE, stroke, or hospitalization elsewhere. │
│ 4. Compromised Intent-to-Treat (ITT) Principles: Missing primary efficacy│
│ data complicates imputation models and regulatory drug approval. │
└──────────────────────────────────────────────────────────────────────────┘
2. Standard Due Diligence Protocol for Unresponsive Participants
Before a Principal Investigator can formally declare a subject Lost to Follow-Up, the research site must execute and thoroughly document a multi-tiered due diligence tracing protocol.
┌──────────────────────────────────────────────────────────────────────────┐
│ MULTI-TIERED DUE DILIGENCE WORKFLOW │
├──────────────────────────────────────────────────────────────────────────┤
│ TIER 1: Multi-Modal Direct Contact Attempts │
│ • Minimum of 3–5 telephone calls conducted at varied times of day │
│ (morning, afternoon, evening) and varied days of the week. │
│ • Secure text messages / emails (if participant authorized in ICF). │
├──────────────────────────────────────────────────────────────────────────┤
│ TIER 2: Designated Secondary / Emergency Contacts Outreach │
│ • Contact secondary individuals authorized by subject at consent. │
│ • STRICT CONFIDENTIALITY: Never disclose disease or trial details; │
│ state only: 'We are trying to reach [Name] regarding an appointment.' │
├──────────────────────────────────────────────────────────────────────────┤
│ TIER 3: Healthcare Provider & Medical Record Network Inquiries │
│ • Contact participant's primary care physician or referring specialist. │
│ • Check institutional EHR systems for recent emergency admissions. │
├──────────────────────────────────────────────────────────────────────────┤
│ TIER 4: Certified Letter with Return Receipt Requested │
│ • Send formal, neutral letter via USPS Certified Mail (or courier). │
│ • Track delivery signature or return envelope in the source file. │
├──────────────────────────────────────────────────────────────────────────┤
│ TIER 5: Public Registry & Vital Statistics Search (If Permitted) │
│ • Check national death registries (e.g., National Death Index / SSDI) │
│ to establish vital status for primary safety endpoints. │
└──────────────────────────────────────────────────────────────────────────┘
Documenting Due Diligence in Source Records
Every single attempt must be recorded contemporaneously in the subject's source chart, detailing:
- Date and exact time of phone call or email.
- Staff member initials and specific phone number dialed.
- Outcome (e.g., "No answer, voicemail full", "Left callback message without disclosing study details").
- Physical tracking proof: The postal tracking number, signed return green card, or returned unopened envelope for certified letters must be permanently filed in the participant's research chart.
3. Participant Right to Withdraw & Consent Management
When a participant expresses a desire to stop participating, research staff must handle the interaction with absolute respect for patient autonomy while clarifying the scope of withdrawal.
A. Inquiring About Reasons for Withdrawal
- Per ICH GCP E6(R3) Annex 1 section 2.9, while a subject is not obligated to give their reasons for withdrawing, the investigator may inquire about the reason(s), while fully respecting the subject's rights.
- Why inquire? Differentiating between withdrawal due to an unreported Adverse Event (e.g., intolerable dizziness, severe nausea) versus logistical burden (e.g., job relocation) is vital for participant safety reporting and pharmacovigilance.
B. The Three Tiers of Study Exit
THE THREE TIERS OF STUDY EXIT
│
┌───────────────────────────────┼───────────────────────────────┐
▼ ▼ ▼
TIER 1: DISCONTINUATION OF TIER 2: PARTIAL WITHDRAWAL TIER 3: COMPLETE WITHDRAWAL
STUDY INTERVENTION (IP ONLY) (MODIFIED SAFETY FOLLOW-UP) OF CONSENT
• Subject stops taking IP • Declines clinic visits • Revokes ALL consent
• AGREES to attend all clinic • AGREES to phone safety checks • Ceases ALL study contact
visits, blood draws, scans • AGREES to survival tracking • No future data collected
• PREFERRED GCP OUTCOME • Preserves critical endpoints • Existing data RETAINED
- Tier 1: Discontinuation of Study Intervention (Treatment Discontinuation Only):
- The subject discontinues taking the investigational drug (e.g., due to an AE or disease progression) but remains in the study, agreeing to complete all scheduled follow-up visits, laboratory evaluations, and endpoint assessments. This is the optimal clinical outcome for maintaining Intent-to-Treat (ITT) validity.
- Tier 2: Partial Withdrawal of Consent (Modified Follow-Up):
- The subject refuses in-person clinic visits or invasive procedures but agrees to periodic telephone safety calls, remote survival status checks, or allows the site to review public vital statistics and hospital medical records.
- Tier 3: Complete Withdrawal of Consent:
- The subject explicitly revokes all consent for further study involvement, refusing any further contact, visits, or future data collection.
4. Regulatory Governance of Data Retention After Consent Withdrawal
A critical area of testing on the ACRP-CP exam is what happens to a participant's data when they withdraw consent.
FDA 2008 Guidance & ICH GCP Standard: When a participant withdraws consent from a clinical trial, all data collected on that participant PRIOR to the withdrawal of consent CANNOT be removed or excised from the trial database.
┌──────────────────────────────────────────────────────────────────────────┐
│ DATA RETENTION AFTER WITHDRAWAL │
├──────────────────────────────────────────────────────────────────────────┤
│ • Data Collected PRIOR to Withdrawal: │
│ - Must remain in the study database and electronic Case Report Forms. │
│ - Essential to maintain scientific validity, statistical modeling, │
│ and complete safety reporting to regulatory authorities. │
│ - Participants CANNOT demand that their historical data be deleted. │
├──────────────────────────────────────────────────────────────────────────┤
│ • Data Generation AFTER Withdrawal: │
│ - If consent is completely withdrawn, site CANNOT perform new study │
│ tests or access the subject's private medical record for new data. │
│ - Exception: Reviewing public records (e.g., publicly available death │
│ registries) to assess survival status is permitted under FDA rules. │
└──────────────────────────────────────────────────────────────────────────┘
5. Early Termination (ET) Visits and Safety Assessments
Whenever a participant discontinues study intervention early or withdraws from the trial, the site should make every reasonable effort to conduct a formal Early Termination (ET) Visit.
A. Essential Components of an Early Termination Visit
- Comprehensive Safety Evaluation: Physical examination, vital signs, 12-lead ECG, and safety laboratory blood/urine panels (to assess organ function and drug toxicities).
- Adverse Event Reconciliation: Thorough evaluation of all ongoing and new adverse events, ensuring resolution or ongoing medical management.
- Investigational Product Reconciliation & Retrieval:
- Collecting all remaining unused investigational products, empty bottles, blister packs, and used devices.
- Performing final pill count and documenting drug accountability.
- Retrieving patient dosing diaries or ePRO devices.
- Safe Clinical Transition of Care:
- The PI must coordinate with the participant's primary care physician to transition the patient to standard-of-care medical therapies.
- If the subject was on a blinded investigational drug that requires gradual dose tapering, the PI must execute a medically supervised taper schedule.
┌─────────────────────────────────────────────────────────────────────────────────────────────────┐
│ WITHDRAWAL & EARLY TERMINATION CHECKLIST │
├──────────────────────────────────────────────────────────────────────┬─────────────┬────────────┤
│ Operational Task │ Performed By│ Documented?│
├──────────────────────────────────────────────────────────────────────┼─────────────┼────────────┤
│ Inquire respectfully about primary reason for withdrawal │ CRC / PI │ [x] Source │
│ Differentiate IP discontinuation vs. partial vs. full consent revoke │ CRC / PI │ [x] Source │
│ Conduct Early Termination clinical safety assessments (vitals, labs) │ PI / Sub-I │ [x] Source │
│ Retrieve all unused IP, packaging, and ePRO diary devices │ CRC │ [x] ISF Log│
│ Reconcile final drug accountability and calculate final compliance │ CRC │ [x] eCRF │
│ Document resolution / follow-up plan for all ongoing Adverse Events │ PI / Sub-I │ [x] eCRF │
│ Send clinical summary letter to participant's primary physician │ PI │ [x] Source │
│ Notify Sponsor and IRB of early withdrawal status │ CRC │ [x] ISF │
└──────────────────────────────────────────────────────────────────────┴─────────────┴────────────┘
A participant enrolled in a Phase III cardiovascular trial fails to attend their Month 6 study visit. Over the subsequent two weeks, the study coordinator places two phone calls during normal business hours but receives no answer. What additional step must the site complete before the participant can be formally classified as Lost to Follow-Up (LTFU)?
Subject 204 experiences persistent Grade 2 nausea and informs the study coordinator that she wants to withdraw from a 12-month oncology trial at Month 3. The subject states she refuses to take any more study pills but does not mind speaking to the nurse by phone every few months. How should the study team classify and manage this situation?
A participant withdraws consent halfway through a 2-year clinical study and demands that the investigator immediately erase and delete all of his previously collected blood test results and clinical trial data from the study database. According to FDA regulations and ICH GCP, how must the investigator respond?